Return to homepagePandemic Pact

BioBlock® Proof of Concept Trial

Grant number: LMVPT22288

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2022
    2023

  • Known Financial Commitments (USD)

    $36,284.71

  • Funder

    Estonian Research Council

  • Principal Investigator

    Kalda Ruth

  • Research Location

    Estonia

  • Lead Research Institution

    University of Tartu

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Clinical trials for disease management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

In pandemic situation of SARS-CoV-2 all actions should be taken to find out new methods to control the dissemination of the virus. By now there are already several vaccines as well medications, what are approved for SARS-CoV-2, however there is still need to continue with clinical research to find new prophylactic as well treatment measures. The aim of the current study is to evaluate efficacy of BioBlock intranasal spray in prevention and curing of SARS-CoV-2 as well safety of this spray among healthy volunteers. Hypothesis 1: Usage of BioBlock nasal spray will lower the contamination in comparison with placebo Hypothesis 2:Usage of Bioblock nasal spray does not cause substantial side effects. 2000 thousand healthy volunteers will be randomised either to the group of nasal spray receives ( 1000 volunteers ) or to the group of placebo receives ( 1000 volunteers) to prove the concept.